Biotech Lock-Up Expiration Hell Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (587)	1/15/2002 9:12:29 AM
From: tuck	of 1005

INGN with another manufacturing win: >>AUSTIN, Texas, Jan. 15 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - news) announced today that it has entered into an agreement with Biogen, Inc. (Nasdaq: BGEN - news) to provide process development and manufacturing services for therapeutic gene delivery systems. Under the multi-year agreement Introgen will generate materials and make recommendations to support Biogen's product development activities in the gene therapy field. Financial terms were not disclosed. ``We look forward to supporting Biogen with Introgen's industry-leading expertise in manufacturing gene delivery systems,'' said James W. Albrecht, Jr., Introgen's chief financial officer. ``We expect our work under this agreement will create material revenues for Introgen in future periods.'' Recently, Introgen was selected to manufacture the worldwide reference material to be used by companies and academic institutions developing adenovirus-based products based on a manufacturing project award from the Williamsburg BioProcessing Foundation. The Office of Cellular and Gene Therapies of the Federal Food and Drug Administration (FDA) advised on the award grant based on competencies and expertise of competing companies. Introgen owns the world's largest safety database for adenoviral vectors and controls key intellectual property in the area of gene therapy applications and viral vector production technology. ``We believe Biogen's selection of Introgen to deliver development and manufacturing services further validates Introgen's strategy of providing the infrastructure and expertise to shorten development timelines and to enhance the value of product candidates for select third parties,'' said Shawn L. Gallagher, Introgen's vice president for product development.<< snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next